Development of Live, Attenuated Hepatitis A Vaccine (H2-strain)
Overview
Authors
Affiliations
Hepatitis A, with high prevalence and high incidence, is one of the most serious infectious diseases in China. A programme aiming at developing a vaccine against hepatitis A has been in progress since 1980. The H2-strain vaccine that had been selected and studied in our laboratory was proven to be attenuated for human beings and has been proven to be effective in preventing hepatitis A. In the near future, the live, attenuated H2-strain vaccine derived from tissue culture will be available in China.
A review of immunogenicity and tolerability of live attenuated Hepatitis A vaccine in children.
Rao S, Mao J, Motlekar S, Fangcheng Z, Kadhe G Hum Vaccin Immunother. 2016; 12(12):3160-3165.
PMID: 27532370 PMC: 5215502. DOI: 10.1080/21645515.2016.1216286.
Mitra M, Shah N, Faridi M, Ghosh A, Sankaranarayanan V, Aggarwal A Hum Vaccin Immunother. 2015; 11(5):1147-52.
PMID: 26018443 PMC: 4514242. DOI: 10.4161/21645515.2014.979646.
Era of vaccination heralds a decline in incidence of hepatitis A in high-risk groups in China.
Fangcheng Z, Xuanyi W, Mingding C, Liming J, Jie W, Qi J Hepat Mon. 2012; 12(2):100-5.
PMID: 22509186 PMC: 3321316. DOI: 10.5812/hepatmon.838.
Shen Y, Gu X, Zhou J World J Gastroenterol. 2008; 14(17):2771-5.
PMID: 18461664 PMC: 2709045. DOI: 10.3748/wjg.14.2771.
H2 strain attenuated live hepatitis A vaccines:protective efficacy in a hepatitis A outbreak.
Zhao Y, Meng Z, Xu Z, Guo J, Chai S, Wang X World J Gastroenterol. 2002; 6(6):829-832.
PMID: 11819704 PMC: 4728270. DOI: 10.3748/wjg.v6.i6.829.